GPCR theme editorial

British Journal of Pharmacology

Volumn 158, Issue 1, 2009, Pages 1-4

  Milligan, G ^a   McGrath, J C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CANNABINOID; CANNABINOID RECEPTOR; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CYCLIC AMP; FATTY ACID; FREE FATTY ACID RECEPTOR 2; FREE FATTY ACID RECEPTOR 3; G PROTEIN COUPLED RECEPTOR; HISTAMINE; LIPOCORTIN 1; MELATONIN; NEUROMEDIN S; NEUROMEDIN U; NEUROPEPTIDE Y; OPIATE DERIVATIVE; OPIATE RECEPTOR; PROSTANOID; PROTEINASE ACTIVATED RECEPTOR 2; PURINE DERIVATIVE; PURINERGIC RECEPTOR; RECEPTOR PROTEIN; SEROTONIN; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; DRUG RECEPTOR BINDING; DRUG RESEARCH; DRUG TARGETING; GASTROINTESTINAL DISEASE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; VIRUS INFECTION;

ANIMALS; DRUG DISCOVERY; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 69249213477     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00422.x     Document Type: Review

References (71)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2 S1 S209.
2. Bailey CP, Oldfield S, Llorente J, Caunt CJ, Teschemacher AG, Roberts L, McArdle CA, Smith FL, Dewey WL, Kelly E, Henderson G (2009). Involvement of PKCα and G-protein-coupled receptor kinase 2 in agonist-selective desensitization of μ-opioid receptors in mature brain neurons. Br J Pharmacol 158 : 157 164.
3. 1 receptors and endogenous ATP in the control of spontaneous mechanical activity in mouse ileum. Br J Pharmacol 158 : 243 251.
4. 2B receptor in rodent large bowel physiology. Br J Pharmacol 158 : 252 258.
5. 3-adrenoceptors in the modulation by SR59230A of the effects of MDMA on body temperature in the mouse. Br J Pharmacol 158 : 259 266.
6. Boengler K (2009). Stimulation of cardiac β-adrenoceptors targets connexin 43. Br J Pharmacol 158 : 195 197.
7. Borland G, Smith BO, Yarwood SJ (2009). EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol 158 : 70 86.
8. Bradley ME, Bond ME, Manini J, Brown Z, Charlton SJ (2009). SB265610 is an allosteric, inverse agonist at the human CXCR2 receptor. Br J Pharmacol 158 : 328 338.
9. 2-adrenoceptor responses in cardiomyocytes derived from human embryonic stem cells: comparison with failing and non-failing adult human heart. Br J Pharmacol 153 : 751 759.
10. Catalucci D, Bang ML, Condorelli G (2008). Deciphering the β-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: closer to clinical use? Br J Pharmacol 153 : 625 626.
11. Charlton SJ (2009). Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 158 : 165 168.
12. Chung S, Funakoshi T, Civelli O (2008). Orphan GPCR research. Br J Pharmacol 153 : S339 S346.
13. Coleman RA (2009). On the mechanism of the persistent action of salmeterol: what is the current position Br J Pharmacol 158 : 180 182.
14. Connor M (2009). Shadows across μ-Star? Constitutively active μ-opioid receptors revisited. Br J Pharmacol 156 : 1041 1043.
15. 1 receptor. Br J Pharmacol 158 : 225 231.
16. D'Acquisto F, Perretti M, Flower RJ (2008). Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol 155 : 152 169.
17. Davis E, Loiacono R, Summers RJ (2008). The rush to adrenaline: drugs in sport acting on the β-adrenergic system. Br J Pharmacol 154 : 584 597.
18. DeFea K (2008). β-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 153 : S298 S309.
19. Divin MF, Bradbury FA, Carroll FI, Traynor JR (2009). Neutral antagonist activity of naltrexone and 6β-naltrexol in naive and opioid-dependent C6 cells expressing a μ-opioid receptor. Br J Pharmacol 156 : 1044 1053.
20. 2-adrenoceptor responses in human airway cells during prolonged exposure. Br J Pharmacol 158 : 169 179.
21. Franco R (2009). G-protein-coupled receptor heteromers or how neurons can display differently flavoured patterns in response to the same neurotransmitter. Br J Pharmacol 158 : 23 31.
22. Franco R, Casadó V, Cortés A, Mallol J, Ciruela F, Ferré S, Lluis C, Canela EI (2008). G-protein-coupled receptor heteromers: function and ligand pharmacology. Br J Pharmacol 153 : S90 S98.
23. 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Br J Pharmacol 158 : 287 299.
24. Gilman AG (1995). Nobel Lecture. G proteins and regulation of adenylyl cyclase. Biosci Rep 15 : 65 97.
25. Giraldo J (2008). On the fitting of binding data when receptor dimerization is suspected. Br J Pharmacol 155 : 17 23.
26. 1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155 : 103 109.
27. Hoffmann C, Zürn A, Bünemann M, Lohse MJ (2008). Conformational changes in G-protein-coupled receptors;the quest for functionally selective conformations is open. Br J Pharmacol 153 : S358 S366.
28. Ingram SL, Traynor JR (2009). Role of protein kinase C in functional selectivity for desensitization at the m-opioid receptor: from pharmacological curiosity to therapeutic potential. Br J Pharmacol 158 : 154 156.
29. Jockers R, Maurice P, Boutin JA, Delagrange P (2008). Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? Br J Pharmacol 154 : 1182 1195.
30. Jones RL, Giembycz MA, Woodward DF (2009). Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol 158 : 104 145.
31. Jopling LA, Watt GF, Fisher S, Birch H, Coggon S, Christie MI (2007). Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay. Br J Pharmacol 152 : 1260 1271.
32. 3 receptors in the conscious rat. Br J Pharmacol 158 : 372 381.
33. Juneja J, Casey PJ (2009). Role of G12 proteins in oncogenesis and metastasis. Br J Pharmacol 158 : 32 40.
34. Kanke T, Kabeya M, Kubo S, Kondo S, Yasuoka K, Tagashira J et al. (2009). Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br J Pharmacol 158 : 361 371.
35. Kelly E, Bailey CP, Henderson G (2008). Agonist-selective mechanisms of GPCR desensitization. Br J Pharmacol 153 : S379 S388.
36. Langley, JN (1905). On the reaction of cells and of nerve endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33 : 374 413.
37. 2-Adrenoceptor polymorphisms and cardiovascular diseases. Br J Pharmacol 158 : 61 69.
38. 4 receptor. Br J Pharmacol 157 : 14 23.
39. Lohse MJ, Hein P, Hoffmann C, Nikolaev VO, Vilardaga J-P, Bünemann M (2008). Kinetics of G-protein-coupled receptor signals in intact cells. Br J Pharmacol 153 : S125 S132.
40. 2 cannabinoid receptors: new vistas. Br J Pharmacol 153 : 177 178.
41. 2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 158 : 382 391.
42. 1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Br J Pharmacol 158 : 232 242.
43. 1A-adrenoceptor and elucidates its relationship to the other subtypes. Br J Pharmacol 158 : 209 224.
44. Milligan G (2008). A day in the life of a G protein-coupled receptor: the contribution to function of G protein-coupled receptor dimerization. Br J Pharmacol 153 : S216 S229.
45. Milligan G (2009). G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br J Pharmacol 158 : 5 14.
46. Milligan G, Stoddart LA Smith NJ (2009). Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3. Br J Pharmacol 158 : 146 153.
47. Mitchell JD, Maguire JJ, Davenport AP (2009). Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S. Br J Pharmacol 158 : 87 103.
48. Mueller A (2007). Internalization: what does it tell us about pharmacokinetic and pharmacodynamic properties of an antagonist? Br J Pharmacol 152 : 1145 1146.
49. 1- adrenoceptor phenotypes in the iris of pigmented and albino rabbits. Br J Pharmacol 158 : 354 360.
50. 1A-adrenoceptor. Br J Pharmacol 155 : 1 3.
51. 2- adrenoceptor mechanisms. Br J Pharmacol 155 : 395 406.
52. Overton HA, Fyfe MCT, Reynet C (2008). GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br J Pharmacol 153 : S76 S81.
53. Parker SL, Balasubramaniam A (2008). Neuropeptide Y Y2 receptor in health and disease. Br J Pharmacol 153 : 420 431.
54. Rodbell M (1995). Nobel Lecture. Signal transduction: evolution of an idea. Biosci Rep 15 : 117 133.
55. Rovira X, Vivó M, Serra J, Roche D, Strange PG, Giraldo J (2009). Modelling the interdependence between the stoichiometry of receptor oligomerization and ligand binding for a coexisting dimer/tetramer receptor system. Br J Pharmacol 156 : 28 35.
56. Salameh A, Krautblatter S, Karl S, Blanke K, Rojas Gomez D, Dhein S. et al. (2009). The signal transduction cascade regulating the expression of the gap junction protein connexin43 by β-adrenoceptors. Br J Pharmacol 158 : 198 208.
57. 2B-adrenoceptor in neuronal cells. Br J Pharmacol 158 : 314 327.
58. 2-adrenoceptor agonist. Br J Pharmacol 158 : 277 286.
59. Scola A-M, Loxham M, Charlton SJ, Peachell PT (2009). The long-acting β-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 158 : 267 276.
60. Sebastião AM, Ribeiro JA (2009). Triggering neurotrophic factor actions through adenosine A2A receptor activation: implications for neuroprotection. Br J Pharmacol 158 : 15 22.
61. 12/13- coupled receptors. Br J Pharmacol 158 : 41 49.
62. Strange PG (2008). Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153 : 1353 1363.
63. Summers RJ (2008). Atypical pharmacologies at β-adrenoceptors. Br J Pharmacol 155 : 285 287.
64. 2- adrenoceptor agonist salmeterol. Br J Pharmacol 158 : 183 194.
65. Talasila A, Germack R, Dickenson JM (2009). Characterization of P2Y receptor subtypes functionally expressed on neonatal rat cardiac myofibroblasts. Br J Pharmacol 158 : 339 353.
66. Tobin AB (2008). G-protein-coupled receptor phosphorylation: where, when and by whom. Br J Pharmacol 153 : S167 S176.
67. 3-adrenoceptors following chronic β-adrenergic stimulation in neonatal rat cardiomyocytes. Br J Pharmacol 158 : 300 313.
68. Wellendorph P, Bräuner-Osborne H (2009). Molecular basis for amino acid sensing by family C G-protein-coupled receptors. Br J Pharmacol 156 : 869 884.
69. Wilson CN (2008). Adenosine receptors and asthma in humans. Br J Pharmacol 155 : 475 486.
70. Zaccolo M (2009). cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol 158 : 50 60.
71. 2A-adenosine receptor: a GPCR with unique features? Br J Pharmacol 153 : S184 S190.